Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

389 results about "Single cell suspension" patented technology

Single-cell suspensions are a prerequisite for experiments in cell separation, cell analysis and cell culture. To avoid tedious and often painful manual dissociations the gentleMACS Dissociator allows one to dissociate tissue very efficiently under controlled and reproducible conditions.

Human amnion mesenchymal stem cell serum-free culture medium and culture method thereof

ActiveCN101914490ANo other animal originPassivityEmbryonic cellsGerm cellsCartilage cellsOsteoblast
The invention relates to a human amnion mesenchymal stem cell serum-free culture medium and a culture method thereof. The culture medium is formed by adding human serum albumin, human transferrin, human insulin and sodium selenite into a DMEM/F12 basic culture medium. The culture method for the culture medium comprises the following steps of: digesting human amnion by using trypsin, then digesting the human amnion by using collagenase IV and deoxyribonuclease I, and filtering the mixture to obtain single cell suspension; and adding the human serum albumin, the transferrin, the insulin and the sodium selenite into the DMEM/F12 basic culture medium in a ratio of VDMEM to VF12 of 1:1, and putting human amnion mesenchymal stem cells in a 37 DEG C CO2 incubator with saturated humidity and volume fraction of 5 percent under the serum-free condition, wherein culture in vitro and amplification are realized by solution change and transfer of culture, potentiality of multi-direction differentiation is maintained, and the amplified cells can be induced in vitro to form cartilage cells, osteoblasts and adipocytes. The culture medium and the culture method have the characteristics of no other animal sources, wide source and no limitation of ethics.
Owner:辽宁艾米奥干细胞与再生医学研究院有限公司

Preparation method and application of collagen scaffold composite bone marrow-derived mesenchymal stem cells (BMSCs)

The invention relates to a preparation method and application of collagen scaffold composite bone marrow-derived mesenchymal stem cells (BMSCs). The preparation method comprises the steps of preparing single cell suspension after trypsinizing the BMSCs, uniformly dropwise adding the single cell suspension to a collagen scaffold, putting the collagen scaffold into an incubator to be cultured, and adding an L-DMEM complete medium to continue culture, thus obtaining the collagen scaffold composite BMSCs. The preparation method has the advantages that the following defects are overcome: endometria are seriously injured as intrauterine adhesion is mechanically separated by adopting hysteroscopic surgery, intrauterine devices or anti-adhesion materials are put after the surgery and estrogens are given after the surgery to promote intima growth; the problem of intima scars can not be solved; functional intima repair can not be achieved; adhesion is very easy to happen again. As active ingredients for treating serious endometrium injury, the BMSCs are convenient to obtain, secrete growth factors to improve the local microenvironment and immunoregulation, have good biocompatibility, degradability and safety, promote scarred endometrium repair and increase the intima thickness and local blood vessel density.
Owner:YANTAI ZHENGHAI BIO TECH

Construction method of human amniotic mesenchymal stem cell bank

The invention relates to a construction method of a human amniotic mesenchymal stem cell bank. The construction method comprises the following steps: taking a human amnion for detection, flushing and washing the human amnion with a phosphate buffered solution, then smashing the human amnion, diluting with the phosphate buffered solution, digesting with trypsin, digesting with collagenase IV and deoxyribonuclease I, and filtering to obtain a single-cell suspension; by adding human serum albumin, transferring, insulin and sodium selenite into a DMEM/F12 basal culture medium with the ratio of VDMEM to VF12 being 1 to 1, placing human amnion mesenchymal stem cells in an incubator under the serum-free condition, and then performing liquid exchange and culture transfer; subjecting the mesenchymal stem cells obtained through in vitro culture and proliferation to liquid nitrogen refrigeration, and preserving the cells according to the gender of newborn infants, the ABO/Rh type and the HLA type; establishing cell information files, so that the human amniotic mesenchymal stem cell bank is constructed. The method has the characteristics of no other animal derivation, wide source range and no ethic limitation. With adoption of the method, the human amniotic mesenchymal stem cells can be provided for cell therapy and other application.
Owner:沈阳艾米奥生物工程技术研发中心有限公司

Preparation method of deciduous tooth mesenchymal stem cells and used kit

The invention discloses a preparation method of deciduous tooth mesenchymal stem cells, comprising the steps of: cleaning and sterilizing the tissue surfaces of deciduous teeth with normal saline and 75% alcohol, preserving the deciduous teeth in deciduous teeth preserving fluid; acquiring dental pulp from the deciduous teeth, adding dental pulp digestive fluid to the dental pulp for digestion; obtaining a unicell suspension; adding cell culture fluid, carrying out centrifuging and cleaning, adding precipitated cells into cell culture fluid, putting the cell culture fluid in a carbon dioxide incubator for culturing; when the primary cell fusion reaches 70%, adding cell washing fluid, shaking the culture bottle for washing cells, sucking and abandoning the cell washing fluid, adding cell digestive fluid for digestion, adding cell culture fluid to terminate digestion, repeatedly beating upon the bottle bottom until the cells completely fall off, adding cell culture fluid, inoculating into a culture bottle, putting the culture bottle in the carbon dioxide incubator for culturing, regarding the cells as P1 generation mesenchymal stem cells; when the P1 generation cell fusion reaches 70-80%, carrying out trypsin digestion, collecting digestive cells, carrying out centrifuging and inoculation; after 3d, carrying out trypsin digestion again, collecting digestive cells, carrying out centrifuging, counting and inoculation, and when the P3 generation cell growth reaches 80%, gathering and cryopreserving the cells.
Owner:ANHUI NEW LIFE STEM CELL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products